Who
Christine Bellon
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Beam Therapeutics.
In numbers
- Trades disclosed
- 45
- Buys
- 0
- Sells
- 15
- Bought
- $0
- Sold
- $2.8M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 30 Mar 2023
- Last trade
- 1 Apr 2026
- Last filed
- 6 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Apr 2026filed 6 Apr 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $146K5,956 at $24.58 | filing |
| 1 Apr 2026filed 6 Apr 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $146K5,956 at $24.58 | filing |
| 31 Mar 2026filed 2 Apr 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 31 Jan 2026filed 2 Feb 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 31 Jan 2026filed 2 Feb 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $47K1,371 at $34.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $47K1,371 at $34.00 | filing |
| 15 Jan 2026filed 20 Jan 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $71K2,111 at $33.62 | filing |
| 15 Jan 2026filed 20 Jan 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $554K15,959 at $34.72 | filing |
| 15 Jan 2026filed 20 Jan 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $20K559 at $35.40 | filing |
| 15 Jan 2026filed 20 Jan 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $71K2,111 at $33.62 | filing |
| 15 Jan 2026filed 20 Jan 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $554K15,959 at $34.72 | filing |
| 15 Jan 2026filed 20 Jan 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $20K559 at $35.40 | filing |
| 31 Dec 2025filed 5 Jan 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $34K1,254 at $27.10 | filing |
| 31 Dec 2025filed 5 Jan 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $34K1,254 at $27.10 | filing |
| 1 Oct 2025filed 3 Oct 2025 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $9,150373 at $24.53 | filing |
| 1 Apr 2025filed 3 Apr 2025 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $104K5,674 at $18.35 | filing |
| 31 Mar 2025filed 2 Apr 2025 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —9,492 at $0.00 | filing |
News
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?BEAM · fool.com · 18 Oct 2026Beam Therapeutics (NASDAQ: BEAM) CEO sells 50,000 shares after option exerciseBEAM · tickerreport.com · 17 Oct 2026Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual CongressBEAM · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Christine Bellon; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.